Comparison of botulinum toxins A and B in the treatment of facial rhytides

Dermatologic Clinics

Volumn 22, Issue 2, 2004, Pages 221-226

  Sadick, Neil S ^a   Matarasso, Seth L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUTRALIZING ANTIBODY;

ACETYLCHOLINE RELEASE; ANTIBODY PRODUCTION; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DIPLOPIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG STORAGE; DYSPEPSIA; DYSPHAGIA; DYSTONIA; ECCHYMOSIS; HEADACHE; HUMAN; IMMUNITY; INJECTION PAIN; LOW DRUG DOSE; NEUROTOXICITY; NONHUMAN; PARALYSIS; PH MEASUREMENT; PRIORITY JOURNAL; PTOSIS; REVIEW; WRINKLE; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; FACE; HUMANS; METALLOENDOPEPTIDASES; NEUROMUSCULAR AGENTS; SKIN AGING;

EID: 2442534746     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00040-8     Document Type: Review

References (26)

1. ASAPS 2000 Statistics on cosmetic surgery. 2001;American Society of Aesthetic and Plastic Surgery, New York
2. Carruthers D.A., Carruthers J.A. Treatment of glabellar frown lines with Clostridium botulinum A exotoxin. J Derm Surg Oncol. 18:1992;17-21
3. Blitzer A., Brin M.F., Keen M.F., Aviv J.E. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 119:1993;1018-1022
4. Guyuron B., Huddleston S.W. Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg. 93:1994;913-918
5. Keen M., Blitzer A., Aviv J., Binder W., Prystowsky J., Smith H., et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind placebo-controlled study. Plast Reconstr Surg. 94:1999;94-99
6. Brashear A., Lew M.F., Dykstra D.D., Comella C.L., Factor S.A., Rodnitzky R.L., et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 53:1999;1439-1446
7. Brin M.F., Lew M.F., Adler C.H., Comella C.L., Factor S.A., Jankovic J., et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 53:1999;1431-1438
8. Kessler K.R., Benecke R. Botulinum toxin: from poison to remedy. Neurotoxicology. 18:1997;761-770
9. Lamanna C. The most poisonous poison. Science. 130:1969;763-772
10. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., et al. Botulinum toxin as a biological weapon. JAMA. 285:2001;1059-1071
11. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther. 19:1982;165-194
12. Callaway J.E., Arezzo J.C., Grethlein A.J. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg. 20:2001;127-136
13. Simpson L.L. Molecular pharmacology of botulinum toxin and tetanus toxins. Annu Rev Pharmacol Toxicol. 26:1986;427-453
14. Olney R.K., Aminoff M.J., Gelb D.J., Lowenstein D.H. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology. 38:1988;1780-1783
15. Fagien S., Brandt F.S. Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery. Clin Plast Surg. 28:2001;127-148
16. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 9:1994;213-217
17. Jankovic J., Schwartz K.S. Response and immunoresistance to botulinum toxin injections. Neurology. 45:1995;1743-1746
18. Zuber M., Sebald M., Bathien N., de Recondo J., Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology. 43:1993;1715-1718
19. Ramirez A.L., Reeck J., Maas C.S. Botulinum toxin type B (Myobloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg. 126:2002;459-467
20. Lowe N.J., Yamauchi P.S., Lask G.P., Patnaik R., Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 4:2002;15-18
21. Sadick N.S. Botulinum toxin type B (Myobloc) for glabellar wrinkles: a prospective open-label response study. Dermatol Surg. 28:2003;817-821
22. Sadick N.S. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2400 and 3000 units for the treatment of glabellar wrinkles. Dermatol Surg. 29:2003;501-507
23. Matarasso S.L. Comparison of botulinum toxin types A and B: a bilateral double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg. 29:2003;7-13
24. Matarasso S.L., Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report of partial lip ptosis following injections into the lateral canthal rhytides. Plast Reconstr Surg. 108:2001;208-214
25. Spencer J.M., Gordon M., Goldberg D.J. Botulinum B treatment of the glabellar and frontalis regions: a dose-response analysis. J Cosmet Laser Ther. 4:2002;19-23
26. Hexsel D.M., De Almeida A.T., Rutowitsch M., De Castro I.A., Silveira V.L., Gabatto D.O., et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin Type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 29:2003;523-529